




Swiss Society of Hematology
Diagnostic Meeting



5th Diagnostic Meeting of the Swiss Society of Hematology

22–23 May 2025
Zentrum Paul Klee, Bern

PROGRAM

Real-Time Broadcasting & Slide Sharing

Uncompressed Clarity


Present your slides with a video stream in real-time to peers without any loss of quality

Foster Collaboration

Benefit from instant exchange and seamless collaboration with one or more colleagues

Accelerate Decision

Obtain second opinion instantly, ensuring rapid and confident diagnostic conclusions



 Scan the QR code


N. Brökers, J. Schanz, Springer-Verlag, Feb 2025

eLearning Platform



Advantages of Virtual Classroom

- Requires only one sample per organ
- Identical cell image for all students
- Classes from anywhere
- Post-microscopy and training 24/7



Free Registration to eLCH Platform
in collaboration with SGH-SSH
powered by smartZoom®



Trusted Distribution Partner in Switzerland

ruwag.ch
lifescience@ruwag.ch



Welcome

We are delighted to welcome you to the 5th Diagnostic Meeting of the Swiss Society of Hematology (SSH-DM), on Thursday and Friday, 22–23 May 2025, at the Zentrum Paul Klee in Bern.

Once again, we have prepared an engaging and dynamic program!

This two-day event is designed to advance the clinical application of resources in hematological diagnostics. It features the traditional **microscopy course** alongside specialized sessions on **hemostasis, flow cytometry, hematology genetics, and immune hematology**. Each course includes a **keynote lecture** from a renowned international expert.

We also offer **crash courses** tailored for less specialized trainees. These sessions cover basics in hemostasis, genetics, flow cytometry, morphology, and immune hematology, delivering essential knowledge in a concise format.

The meeting is open to clinicians, pathologists, geneticists, molecular hematology specialists, immunologists, biologists with expertise in hematological diagnostics, specialists in laboratory medical analytics (FAMH), biomedical analysts (BMA), students, and anyone interested in the clinical diagnostics of hematology.

We look forward to welcoming you to this exceptional event!

Prof. Dr. André Tichelli



on behalf of the Scientific Organising Committee



Platelet Aggregation

INSTRUMENTE DER NÄCHSTEN GENERATION intelligent benutzerfreundlich präzise

- › Gold-Standard - Light Transmission Aggregometry (LTA)
- › Messungen im Infrarot-Bereich für weniger Interferenzen
- › CE-markierte Aktivatoren
- › Intuitive Software

*Zur Diagnose von Thrombozyten Funktionsstörungen /
Plättchenhemmer Überwachung / HIT Bestätigung /
Charakterisierung der VWF Krankheiten*



WITH STAGO EXPERTISE
(expert assistance, webinars, booklet,
practical manual about platelets...)



Stago CH S.A.
Sägereistrasse 20
CH-8152 Glattbrugg
+41 (0)43 497 27 55
info@ch.stago.com
www.stago.ch

Scientific Organising Committee

Prof. Dr. med. Anne Angelillo-Scherrer

Inselspital, Universitätsspital Bern

Prof. Dr. med. Ulrike Bacher

Inselspital, Universitätsspital Bern

Prof. Dr. med. Dr. rer. nat. Stefan Balabanov

University Hospital Zürich

PD Dr. med. et phil. nat. Yara Banz

IGMP, Universität Bern

Prof. Dr. med. Sabine Blum

Centre hospitalier universitaire vaudois, Lausanne

Dr. med. Carmen de Ramon Ortiz

Hopitaux universitaires de Geneve

Dr. rer. nat. Jan Dirks

University Hospital Basel

Prof. Dr. med. Stefan Dirnhofer

University Hospital Basel

Dr. med. Charlotte Engström

Blutspende Zürich Schlieren

PD Dr. med. Jeroen Goede

Kantonsspital Winterthur

Dr. phil. nat. Bijan Moshaver

Inselspital, Universitätsspital Bern

Prof. Dr. med. Alicia Rovó

Inselspital, Universitätsspital Bern

Dr. med. Kaveh Samii

Hôpitaux universitaires de Genève

Prof. Dr. med. Georg Stüssi

Ente Ospedaliero Cantonale, Bellinzona

Prof. Dr. med. André Tichelli

University Hospital Basel

Dr. med. Nadija Wegener

University Hospital Zürich

Dr. med. Corinne Widmer

University Hospital Basel

Program overview

Thursday, 22nd May 2025

	Auditorium	Forum	Seminar II Nord
09:00	Registration		
10:00	Hemostasis Crash Course	Flow cytometry Speaker sessions	Genetics Crash Course
11:30	Coffee break & Exhibition (30')		
12:00	Hemostasis Diagnostic pitfalls & solutions	Genetics & Flow cytometry Keynotes	
13:45	Lunch break & Exhibition (45')		
14:30	Hemostasis Artificial intelligence	Genetics Case presentations	Flow cytometry Crash Course
16:15	Apéro & Exhibition (60')		

- Hemostasis
- Flow cytometry/Genetics
- Microscopy
- Immune hematology & Transfusion medicine

Program overview

Friday, 23rd May 2025

	Auditorium	Seminar II Nord
09:00	Registration	
09:00	Microscopy Course Crash Course Morphology Case presentation	
10:30	Coffee break & Exhibition (30')	
11:00	Microscopy Case presentation Keynote Morphology	Immune hematology & Transfusion medicine Keynote Case presentation
13:00	Lunch break & Exhibition (60')	
14:00	Microscopy Case presentations All about Blood – Quiz	
16:30	End of SSH-DM 2025	

Program

 Hemostasis

 Flow cytometry/Genetics

Thursday, 22nd May 2025

Auditorium	Hemostasis <i>Chairs: Bernhard Gerber & Sabine Ruosch</i>	Forum	Flow Cytometry <i>Chairs: Bijan Moshaver & Jan Dirks</i>	Seminar room	Genetics
10:00 – 11:30	Crash course – Hemostasis <i>Lorenzo Alberio, Lausanne Maria Martinez, Basel Jan-Dirk Studt, Zürich</i>	10:00 – 10:45	Telomere length assessment by flow cytometry <i>Elisa Borghi, Bern</i>	10:00 – 11:30	From Zero to Hero <i>Friedel Wenzel & Darius Juškevičius, Basel</i>
		10:45 – 11:30	Leukemic Stem Cells in AML <i>Bijan Moshaver, Bern</i>		
11:30 – 12:00	Foyer Coffee break & Exhibition				
Auditorium	Diagnostic pitfalls and solutions <i>Chairs: Anne Angelillo-Scherrer & Lars Asmis</i>	Forum	Flow & Genetics <i>Chairs: Corinne Widmer & Bijan Moshaver</i>		
12:00 – 12:35	Thrombophilia testing in the anticoagulated patient <i>Patrick Bättig, Basel</i>	12:00 – 12:10	Presentation of speakers		
12:35 – 13:10	Laboratory testing in hemophilia: impact of novel factor and non-factor replacement therapies <i>Lukas Graf, St. Gallen</i>	12:10 – 12:55	Keynote Genetics Molecular Diagnostics in Acute Lymphoblastic Leukemia <i>Lorenz Bastian, Kiel (DE)</i>		
		13:10 – 13:45	Antiphospholipid Syndrome – the ISTH-SSC Guidance <i>Pierre Fontana, Geneva</i>		
13:45 –14:30	Foyer Lunch break & Exhibition				
Auditorium	Artificial intelligence <i>Chairs: Alessandro Casini & Eugenia Biguzzi</i>	Forum	Genetics <i>Chairs: Ilaria Scarpelli & Gertrud Wiedemann</i>	Seminar room	Crash Course – Flow cytometry <i>Chair: Bijan Moshaver</i>
14:30 – 15:15	Keynote Hemostasis Artificial intelligence in medicine <i>Catherine Jutzeler, Zürich</i>	14:45 – 15:15	Case presentation from Kispi ZH <i>Susanne Kubetzko, Zürich</i>	14:45 –15:30	Diagnosis and follow up of B cell lymphoma by spectral flow cytometry <i>Cassandra Hogan, Geneva</i>
15:15 – 15:45	AI projects in hemostasis <i>Michael Nagler, Bern</i>	15:15 – 15:45	Case presentation from Aarau <i>Britta Hartmann & Paula Fernandez, Aarau</i>	15:30 –16:15	
15:45 – 16:15	AI projects in hematology <i>Jeremy Deuel, Zürich</i>	15:45 – 16:15	Case presentation from Bern <i>Sara Meyer & Joëlle Tchinda, Bern</i>		
16:15 – 17:15	Foyer Apéro & Exhibition				

Program

Microscopy

Immune hematology & Transfusion medicine

Friday, 23rd May 2025

Auditorium	Microscopy <i>Chair: André Tichelli</i>		
09:00 – 09:10	Microscopy course welcome <i>Alicia Rovó, Bern</i>		
09:10 – 10:30	Crash course in morphology <i>Jeroen Goede, Winterthur</i>		
10:00 – 10:30	Case presentation <i>Thomas Lehmann, St. Gallen</i>		
10:30 – 11:00	Foyer Coffee break		
Auditorium	Microscopy <i>Chair: Stefani Parmentier</i>	Seminar room	Immune hematology & Transfusion medicine <i>Chairs: Charlotte Engström & Stefan Meyer</i>
11:00 – 11:30	From microscope to diagnosis <i>Myriam Legros, Bern</i>	11:00 – 11:30	Keynote Immune hematology Autoimmune hemolytic anemia – behind the scenes <i>Sacha Zeerleder, Luzern</i>
11:30 – 12:00	Case presentation <i>Thomas Longval, Geneva / Pathologist: Kristof Egervari, Geneva</i>	11:30 – 12:00	iABO transplant & beyond <i>Adrian Bachofner, Zürich</i>
12:00 – 13:00	Keynote Morphology <i>Chair: Alicia Rovó</i> When is CML not CML? – The art of morphology is alive <i>Guy Hannah, London (UK)</i>	12:00 – 12:30	New blood group systems & antigens recently acknowledged by ISBT Working Party for Red Cell Immunogenetics and Blood Group Terminology <i>Christoph Gassner, Triesen (LI)</i>
		12:30 – 13:00	Case presentations <i>Young-Lan Song & Adriana Komarek, Zürich</i>
13:00 – 14:00	Foyer Lunch break & Exhibition		
Auditorium	Microscopy <i>Chair: Kaveh Samii</i>		
14:00 – 14:30	Dysplasias – MDS, its relatives and false friends <i>Anne Marie Asemisen, Flensburg (DE)</i>		
14:30 – 15:00	Case presentation <i>Jean-François Lambert, Nyon & Kristof Egervari, Geneva</i>		
15:00 – 15:30	<i>Chair: Jeroen Goede</i> Case presentation <i>Stefan Balabanov, Zürich & Stefan Dirnhofer, Basel</i>		
15:30 – 16:15	All about Blood – Quiz <i>Alicia Rovó, Bern</i>		
16:15 – 16:30	Closing words and farewell <i>Jeroen Goede, Winterthur</i>		

General information

WIFI

Name: ZPK-Events
PW: eventimklee20

Congress Secretariat & Registration

Meister ConCept GmbH
Bahnhofstrasse 55
5001 Aarau
+41 (0) 62 836 20 90
ssh-dm@meister-concept.ch

Congress venue

Zentrum Paul Klee
Monument im Fruchtländ 1
3001 Bern

Exhibition hours

Thursday, 22 May 2025
09:30 – 17:15
Friday, 23 May 2025
08:30 – ca. 14:15

Helpdesk during the congress

+41 (0) 62 836 20 90
ssh-dm@meister-concept.ch
Thursday, 22 May 2025,
09:00 – 16:15
Friday, 23 May 2025,
08:30 – 16:30

Language

English

Lunch and Coffee

Catering during coffee and lunch breaks will be served in the exhibition area

Networking Apéro

Thursday, 22 May 2025
16:15 – 17:15 at the exhibition area

Accreditation

SSH: 11 credits
(Thursday 5 / Friday 6)
SSPath: 11 credits
(Thursday 5 / Friday 6)
FAMH: 11 credits
(Thursday 5 / Friday 6)

Certificate

The certificate of attendance will be available for download from Friday, 23 May in the afternoon. Please log in with the same e-mail address and password that you used for your registration.

Sponsors

Platinum Sponsor



Gold Sponsors



Silver Sponsors



More Sponsors

AbbVie

Blueprint Medicines

Medion Grifols Diagnostics AG

Pfizer AG

Scopio Labs

Timeline of JAK2 inhibitors:

- 1963: Desferal® (desferrioxamine)
- 2001: glivec® (imatinib)
- 2005: EXJADE (etoposide)
- 2007: Tasigna (tositumomab)
- 2010: REVOLADE® (etomidate)
- 2012: JAKAVI (ruxolitinib)
- 2017: RYDAPT (regorafenib)
- 2018: JADENU (jagtarin)
- 2022: SCSEMBLIX® (sacitinib)
- 2024: FABHALTA (fapirapant)



NOVARTIS | Reimagining Medicine



Langzeitdaten zur subkutanen Prophylaxe bei Hämophilie A – eine Dekade voller Sicherheit und Vertrauen^{1,2}



NEUE VIAL-GRÖSSE
12 mg / 0.4 ml

UM DIE BEHANDLUNG AUCH FÜR DIE
KLEINSTEN MÖGLICHST INDIVIDUELL
ANPASSEN ZU KÖNNEN³



NEUE VIAL-GRÖSSE

300 mg / 2.0 ml

**ERLEICHTERTE BEHANDLUNG:
EINMAL ALLE VIER WOCHEN³**

[illegible]

Roche Pharma (Schweiz) AG • Grenzacherstrasse 124 • 4058 Basel
M-CH-00004731-11/2024



BRUKINSA® 80 mg Hartkapseln

Dieses Arzneimittel unterliegt einer zusätzlichen Überwachung. Dies ermöglicht eine schnelle Identifizierung neuer Erkenntnisse über die Sicherheit. Angehörige von Gesundheitsberufen sind aufgefordert, jeden Verdachtsfall einer Nebenwirkung zu melden. **Indikation (I):** BRUKINSA® (Zaricorbutin) wird als Monotherapie zur Behandlung von erwachsenen Patientinnen und Patienten mit Morbus Waldenström (WM) angewendet, die mindestens eine vorangehende Therapie erhalten haben oder zur Erstlinientherapie bei erwachsenen Patientinnen und Patienten, welche für eine Chemo-Immuntherapie nicht in Frage kommen. BRUKINSA® ist indiziert als Monotherapie für die Behandlung von erwachsenen Patienten mit chronisch lymphatischer Leukämie (CLL), die mindestens eine Vortherapie erhalten haben. BRUKINSA® in Kombination mit Obinutuzumab ist indiziert für die Behandlung erwachsener Patienten mit refraktärem oder rezidivierendem follikulärem Lymphom (FL) Grad 1-3, welche mindestens zwei vorhergehende Therapien, einschliesslich einer anti-CD20 Antikörpertherapie erhalten haben. **Dosierung (D):** Die übliche Dosis beträgt 320 mg täglich zur Einnahme, entweder einmal (4 Kapseln) oder zweimal täglich (je zwei Kapseln morgens und abends). **Kontraindikationen (K):** Überempfindlichkeit gegen den Wirkstoff oder einen der sonstigen Bestandteile. **Interaktionen (I):** BRUKINSA® wird hauptsächlich durch das Cytochrom P450 CYP3A4 (CYP3A) metabolisiert. Die gleichzeitige Anwendung von BRUKINSA® und Arzneimitteln, die CYP3A stark oder mässig hemmen, kann die Exposition erhöhen; die gleichzeitige Anwendung von BRUKINSA® mit starken oder mässigen CYP3A Induktoren kann die Plasmakonzentration verringern. BRUKINSA® ist ein schwacher Induktor von CYP3A und CYP2C9; die gleichzeitige Anwendung kann die Plasmakonzentration dieser Substrate verringern. **Schwangerschaft (S):** BRUKINSA® sollte während der Schwangerschaft nicht angewendet werden. Geeignete hormonelle und Barrierereverwendungsmethoden müssen angewendet werden. **Unerwünschte Wirkungen (U):** Sehr häufig: Thrombozytopenie, Infektion der oberen Atemwege, Blutergüsse, Neutropenie, Blutungen/Hämatome, Erschöpfung, Muskel- und Skelettschmerzen, Hautausschlag, Pneumonie, Husten, Durchfall, Prolongation, Anämie, Bluthochdruck, Arthralgie, Harnwegsinfektion, Verstopfung, Schwindel, Rückenschmerzen, Hämaturie, Asthenie, Alaninaminotransferase, Aspartataminotransferase, Bilirubin, Kreatinin oder Ureat im Blut erhöht. Häufig: Peripheres oder Nicht-melanomartiges Hautkrebs, Epistaxis, Pruritus, Pektelien, Vorfälle im Mund- und -flattern, Purpura, Bronchitis, interstitielle Lungenerkrankung, Ekchymose, febrile Neutropenie. Gelegentlich: Gastrointestinale Blutung, Hepatitis-B-Reaktivierung, Tumorstressyndrom, toxische epidermale Nekrolyse. **Nicht bekannt:** Generalisierte exfoliative Dermatitis. **Zulassungsinhaber (Z):** Beigene Switzerland GmbH, Aeschengraben 27, 4051 Basel, Email: switzerland_affiliate@beigene.com, Servicehotline für Rückfragen zum Produkt: Tel: 0800 005 647. **Abgabekategorie:** A. **Ausführliche Informationen:** Siehe Fachinformation. www.swissmedinfo.ch **Stand der Information:** November 2023

[illegible]5th Diagnostic Meeting of the Swiss Society of Hematology — 15

Faculty

Title	Name	Surname	Institution	Country
Prof. Dr.	Lorenzo	Alberio	Centre hospitalier universitaire vaudois, Lausanne	Switzerland
Prof. Dr.	Anne	Angelillo-Scherrer	Inselspital, Universitätsspital Bern	Switzerland
Dr.	Anne Marie	Asemissen	Malteser Krankenhaus St. Franziskus-Hospital, Flensburg	Germany
PD Dr.	Lars	Asmis	Hirslanden Zürich	Switzerland
Dr.	Adrian	Bachofner	University Hospital Zürich	Switzerland
Prof. Dr.	Stefan	Balabanov	University Hospital Zürich	Switzerland
Dr.	Lorenz	Bastian	Universitätsklinikum Schleswig-Holstein, Kiel	Germany
Dr.	Patrick	Bättig	University Hospital Basel	Switzerland
Dr. med.	Yara	Banz	University Bern	Switzerland
Dr.	Eugenia	Biguzzi	Ente Ospedaliero Cantonale, Bellinzona	Switzerland
Dr. PhD	Elisa	Borghi	Inselspital, Universitätsspital Bern	Switzerland
Prof. Dr.	Alessandro	Casini	Hôpitaux Universitaires de Genève	Switzerland
PD Dr.	Jeremy	Deuel	University Hospital Zürich	Switzerland
Dr.	Jan	Dirks	University Hospital Basel	Switzerland
Prof. Dr.	Stefan	Dirnhofer	University Hospital Basel	Switzerland
Dr.	Ewa	Dudkiewicz	University Hospital Zürich	Switzerland
Dr.	Kristof	Egervari	Hôpitaux Universitaires de Genève	Switzerland
Dr.	Charlotte	Engström	Blutspende Zürich Schlieren	Switzerland
Dr.	Paula	Fernandez	Kantonsspital Aarau	Switzerland
Prof. Dr.	Pierre	Fontana	Hôpitaux Universitaires de Genève	Switzerland
Prof. Dr.	Christoph	Gassner	Private Universität im Fürstentum Liechtenstein, Triesen	Liechtenstein
PD. Dr.	Bernhard	Gerber	IOSI - Istituto Oncologico della Svizzera Italiana	Switzerland
PD Dr.	Jeroen	Goede	Kantonsspital Winterthur	Switzerland
Dr.	Lukas	Graf	Zentrum für Labormedizin, St. Gallen	Switzerland

Title	Name	Surname	Institution	Country
Dr.	Guy	Hannah	King's College Hospital, London	United Kingdom
Dr.	Britta	Hartmann	Kantonsspital Aarau	Switzerland
Dr.	Cassandra	Hogan	Hôpitaux Universitaires de Genève	Switzerland
Dr.	Darius	Juškevičius	University Hospital Basel	Switzerland
Prof. Dr.	Catherine	Jutzeler	ETH Zürich	Switzerland
Dr.	Adriana	Komarek	Blutspende Zürich Schlieren	Switzerland
Dr.	Susanne	Kubetzko	Universitäts-Kinderspital Zürich	Switzerland
Dr.	Jean-François	Lambert	Hôpital de Nyon	Switzerland
	Myriam	Legros	Inselspital, Universitätsspital Bern	Switzerland
Dr.	Thomas	Lehmann	Kantonsspital St. Gallen	Switzerland
Dr.	Thomas	Longval	Hôpitaux Universitaires de Genève	Switzerland
Prof. Dr.	Maria	Martinez	University Hospital Basel	Switzerland
Prof. Dr.	Sara	Meyer	Inselspital, Universitätsspital Bern	Switzerland
Dr.	Stefan	Meyer	Blutspende Zürich Schlieren	Switzerland
Dr.	Bijan	Moshaver	Inselspital, Universitätsspital Bern	Switzerland
Prof. Dr.	Michael	Nagler	Inselspital, Universitätsspital Bern	Switzerland
Dr.	Stefani	Parmentier	St. Claraspital / University Hospital Basel	Switzerland
Dr.	Richard	Ratei	Helios Klinikum Bad Saarow	Germany
Prof. Dr.	Alicia	Rovó	Inselspital, Universitätsspital Bern	Switzerland
Dr.	Sabine	Ruosch	Luzerner Kantonsspital	Switzerland
Dr.	Kaveh	Samii	Hôpitaux Universitaires de Genève	Switzerland
M Sc	Ilaria	Scarpelli	Dr. Risch Labormedizin	Switzerland
pract. med.	Young-Lan	Song	Stadtspital Zürich Triemli & Blutspende Zürich Schlieren	Switzerland
PD Dr.	Jan-Dirk	Studt	University Hospital Zürich	Switzerland
PD Dr.	Joëlle	Tchinda	Inselspital, Universitätsspital Bern	Switzerland
Prof. Dr.	André	Tichelli	University Hospital Basel	Switzerland
Dipl.-Biol.	Friedel	Wenzel	University Hospital Basel	Switzerland
Dr.	Corinne	Widmer	University Hospital Basel	Switzerland
Dr.	Gertrud	Wiedemann	Inselspital, Universitätsspital Bern	Switzerland
Prof. Dr. Dr.	Sacha	Zeerleder	Luzerner Kantonsspital	Switzerland



1. Johnson & Johnson, Fokus Bereich, Onkologie / Hämatologie.
<https://bit.ly/4b7lW4s>, Zuletzt abgerufen 10.2.2025.
2. Swissmedic, Erweiterte Liste zugelassene Humanarzneimittel.
<https://bit.ly/4hSQ8mU>, Stand: 31.01.2025.
3. Johnson & Johnson Innovative Medicine, Johnson & Johnson to showcase strength of its broad hematology portfolio.
<https://bit.ly/4hZTP54>, Stand: 19.11.2024.

**Mehr erfahren
auf unserer
J&J Medical Cloud**

Johnson & Johnson

CP-493233_12/2024
Janssen-Cilag AG, a Johnson & Johnson company, Gubelstrasse 34, 6300 Zug




Activate your coagulation powers

www.sysmex.ch/haemostaseologie

[illegible]

For your mIDH1 patients, in 1L

TIBSOVO® + AZA :
29,3 MONTHS
OVERALL
SURVIVAL¹



SERVIER
moved by you

1L: first line, AZA: azacitidine, mIDH1: mutant isocitrate dehydrogenase 1

1. De Botton S et al. Presented at ASCO 2023 Meeting (#P142) Updated efficacy and safety data from the agile study in patients

with newly-diagnosed acute myeloid leukemia treated with ivosidenib + azacitidine compared to placebo + azacitidine. The reference is available upon request.

TIBSOVO®: ▼ This medicine is subject to additional monitoring. For more information, see the TIBSOVO® physician information on www.swissmedinfo.ch. **WARNING: DIFFERENTIATION SYNDROME IN ACUTE MYELOID LEUKEMIA.** **C:** film-coated tablets 250mg of ivosidenib, excipients lactose and sodium. **I:** *Acute Myeloid Leukaemia (AML)*; in combination with azacitidine for the treatment of adult patients with newly diagnosed AML with an IDH1-R132 mutation who are not eligible to receive intensive induction chemotherapy. Patients with acute promyelocytic leukaemia are excluded. **Cholangiocarcinoma (CCA):** in monotherapy for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 mutation whose disease has progressed after at least one line of systemic therapy. **D:** **CCA:** recommended dose 500 mg ivosidenib (2 x 250 mg tablets) once daily taken orally. **AML:** recommended dose 500 mg ivosidenib (2 x 250 mg tablets) once daily taken orally. To be started on Cycle 1 Day 1, in combination with azacitidine at 75 mg/m² of body surface area, i.v. or subcutaneously, once daily on Days 1-7 of each 28-day cycle. **PRECAUTIONS** prior to administration and monitoring: ECG to perform prior to treatment administration (QTc < 450 msec) and 1x/week during the first 3 weeks. Complete blood count and blood chemistries. Concomitant administration of moderate or strong CYP3A4 inhibitors, differentiation syndrome, leukocytosis, QTc interval prolongation, Guillain-Barré syndrome, Posterior Reversible Encephalopathy Syndrome, Progressive Multifocal Leukoencephalopathy and grade 3 or higher adverse reactions. **CI:** Hypersensitivity to the active substance / excipients. Concomitant administration of strong CYP3A4 inducers or dabigatran. Congenital long QT syndrome. Familial history of sudden death or polymorphic ventricular arrhythmia. QT/QTc interval > 500 msec. Pregnancy, breastfeeding. **W:** *Differentiation syndrome in patients with AML:* Differentiation syndrome may be life threatening or fatal if not treated. Inform patients of signs and symptoms, and to contact their physician immediately and the need to carry the Patient Alert Card with them at all times. Interrupt treatment with Tibsovo if severe signs/symptoms persist for more than 48 hours after the initiation of systemic corticosteroids. **DT:** Interval prolongation, Guillain-Barré syndrome, Posterior Reversible Encephalopathy Syndrome, Progressive Multifocal Leukoencephalopathy. **Haemorrhage.** Hepatic impairment. CYP3A4 substrates. Severe renal impairment. Women of childbearing potential / contraception. **IA:** Contraindicated: strong CYP3A4 inducers; dabigatran. Not recommended: moderate or strong CYP3A4 inhibitors; medicinal products known to prolong QTc interval; CYP3A4, CYP2B6, CYP2C8 or CYP2C9 substrates with a narrow therapeutic index, or CYP2C19 substrates; OAT3 or OATP1B1/1B3 substrates; itraconazole or ketoconazole; UGT substrates. **Precautions:** hormonal contraceptives. **AE:** **AML:** very common: leukocytosis, thrombocytopenia, platelet count decreased, neutropenia, white blood cell count decreased, differentiation Syndrome, electrocardiogram QT prolonged, insomnia, dizziness, headache, vomiting, arthralgia, back pain, pain in extremity, fatigue, epistaxis. **Common:** neutrophil count decreased, leukopenia, neuropathy peripheral, haemorrhage intracranial, oropharyngeal pain, gingival bleeding, pulmonary embolism, petechiae, haematoma. **Uncommon:** Guillain-Barré syndrome, posterior reversible encephalopathy syndrome, progressive multifocal leukoencephalopathy. **CCA:** very common: anaemia, decreased appetite, headache, nausea, abdominal pain, diarrhoea, vomiting, ascites, rash, fatigue. **Common:** electrocardiogram QT prolonged, neuropathy peripheral, rectal haemorrhage, gastrointestinal haemorrhage, upper gastrointestinal haemorrhage, AST and ALT increased, hyperbilirubinemia, jaundice cholestatic, fall, epistaxis, pulmonary embolism. **P:** pack of 60 film-coated tablets. **[A].** Updated information: October 2023. The complete information is available at www.swissmedinfo.ch. Servier (Suisse) S.A., 1202 Genève.

Ad_Tib_SSH 2025_EN_04/25